Cns Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CNSP Stock | USD 3.12 0.41 15.13% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Cns Pharmaceuticals is 'Strong Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Cns Pharmaceuticals within the specified time frame.
Check out Cns Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Cns and provide practical buy, sell, or hold advice based on investors' constraints. Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Cns |
Execute Cns Pharmaceuticals Buy or Sell Advice
The Cns recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cns Pharmaceuticals. Macroaxis does not own or have any residual interests in Cns Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cns Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cns Pharmaceuticals Trading Alerts and Improvement Suggestions
| Cns Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cns Pharmaceuticals has high historical volatility and very poor performance | |
| Cns Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Cns Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Downs Christopher of 66666 shares of Cns Pharmaceuticals at 0.3 subject to Rule 16b-3 |
Cns Pharmaceuticals Returns Distribution Density
The distribution of Cns Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Cns Pharmaceuticals' future price movements. The chart of the probability distribution of Cns Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Cns Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cns Pharmaceuticals returns is essential to provide solid investment advice for Cns Pharmaceuticals.
| Mean Return | -0.33 | Value At Risk | -10.84 | Potential Upside | 10.64 | Standard Deviation | 8.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cns Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cns Stock Institutional Investors
The Cns Pharmaceuticals' institutional investors refer to entities that pool money to purchase Cns Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Goldman Sachs Group Inc | 2024-12-31 | 40.3 K | Mccormack Advisors International | 2024-12-31 | 2 K | Bank Of America Corp | 2024-12-31 | 440 | Sbi Securities Co Ltd | 2024-12-31 | 105 | Synergy Investment Management, Llc | 2024-12-31 | 9.0 | Wells Fargo & Co | 2024-12-31 | 4.0 | Global Retirement Partners, Llc. | 2024-09-30 | 2.0 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 419.7 K | Geode Capital Management, Llc | 2024-12-31 | 387.1 K |
Cns Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 6.8M | (9.0M) | 5.1M | (9.5M) | (8.6M) | (8.1M) | |
| Net Borrowings | 886.7K | (35K) | (88.1K) | (477.5K) | (429.7K) | (408.3K) | |
| Depreciation | 11.1K | 13.1K | 11.8K | 4.1K | 4.8K | 7.2K | |
| Capital Expenditures | 17.9K | 5.7K | 4.4K | 3.9K | 3.5K | 3.3K | |
| Net Income | (9.5M) | (14.0M) | (15.3M) | (18.9M) | (17.0M) | (16.1M) | |
| End Period Cash Flow | 14.0M | 5.0M | 10.1M | 548.7K | 631.0K | 599.5K | |
| Change To Netincome | 6.6M | 627.1K | 1.3M | 1.7M | 1.6M | 1.7M | |
| Free Cash Flow | (7.3M) | (13.5M) | (10.6M) | (14.1M) | (12.7M) | (13.4M) | |
| Other Non Cash Items | 1.6K | 714.9K | 337.2K | 498.0 | 448.2 | 425.79 | |
| Investments | (17.9K) | (5.7K) | (4.4K) | (1.7K) | (2.0K) | (2.1K) |
Cns Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cns Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cns Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cns stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.29 | |
β | Beta against Dow Jones | 0.43 | |
σ | Overall volatility | 9.07 | |
Ir | Information ratio | -0.03 |
Cns Pharmaceuticals Volatility Alert
Cns Pharmaceuticals is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cns Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cns Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cns Pharmaceuticals Fundamentals Vs Peers
Comparing Cns Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cns Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Cns Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cns Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cns Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cns Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cns Pharmaceuticals to competition |
| Fundamentals | Cns Pharmaceuticals | Peer Average |
| Return On Equity | -10.19 | -0.31 |
| Return On Asset | -2.24 | -0.14 |
| Current Valuation | (2.88 M) | 16.62 B |
| Shares Outstanding | 40.75 M | 571.82 M |
| Shares Owned By Insiders | 1.20 % | 10.09 % |
| Shares Owned By Institutions | 0.70 % | 39.21 % |
| Number Of Shares Shorted | 3.93 M | 4.71 M |
| Price To Earning | (13.70) X | 28.72 X |
| Price To Book | 1.21 X | 9.51 X |
| EBITDA | (18.86 M) | 3.9 B |
| Net Income | (18.85 M) | 570.98 M |
| Cash And Equivalents | 8.96 M | 2.7 B |
| Cash Per Share | 0.22 X | 5.01 X |
| Total Debt | 300.81 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 12.34 X | 2.16 X |
| Book Value Per Share | (2.98) X | 1.93 K |
| Cash Flow From Operations | (14.14 M) | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | (352.97) X | 3.12 X |
| Target Price | 0.5 | |
| Number Of Employees | 3 | 18.84 K |
| Beta | 1.05 | -0.15 |
| Market Capitalization | 5.28 M | 19.03 B |
| Total Asset | 1.7 M | 29.47 B |
| Retained Earnings | (69.57 M) | 9.33 B |
| Working Capital | (4.54 M) | 1.48 B |
| Current Asset | 6.61 M | 9.34 B |
| Current Liabilities | 488.66 K | 7.9 B |
| Net Asset | 1.7 M |
Note: Acquisition by Downs Christopher of 66666 shares of Cns Pharmaceuticals at 0.3 subject to Rule 16b-3 [view details]
Cns Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cns . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cns Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Cns Pharmaceuticals? Buying financial instruments such as Cns Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cns Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Defense Thematic Idea Now
Defense
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Defense theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Defense Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.